Lizhu Pharmaceutical Group Co., Ltd. was founded in January 1985 with a registered capital of 953 million yuan. It is a comprehensive pharmaceutical group company integrating pharmaceutical R & D, production and sales. It now employs more than 9000 people. In 1993, Lizhu A shares and B shares were listed one after another; in 2014, the company completed the conversion of B shares into H shares, which is one of the few A + H share pharmaceutical listed companies in the capital market.
In 2019, the company has total assets of 17.976 billion yuan, annual operating income of 9.385 billion yuan, net profit of 1.462 billion yuan and R & D investment of 827 million yuan.
Lizhu is committed to ensuring the effectiveness, safety and stability of the products. The pharmaceutical enterprises of the group have established a sound quality management system. By 2019: 31 production lines of 4 pharmaceutical enterprises have passed GMP certification; 28 varieties of 4 API enterprises have passed GMP certification, another 11 varieties have passed GMP certification of veterinary drugs; 15 varieties of APIs have passed international certification and 20 international certification certificates have been obtained.
The company has more than 400 varieties of API, chemical medicine, proprietary Chinese medicine, biological medicine, biochemical medicine and diagnostic reagent, and more than 90 varieties are produced and sold, involving digestion, cardio-cerebrovascular, reproductive endocrine, mental / nervous, anti-infection, anti-tumor and other fields.
Among them, the leading products in the field of digestion are: Yi Li'an (Alprazole Enteric coated tablets / National Class 1 New drugs; Alprazole Sodium injection / National Class 2 New drugs), Lizhu Dele Series (Bismuth potassium Citrate granules / tablets / capsules, Jindele, Weisanlian), Rabeprazole, Lizhu Changle (Bifidobacterium live bacteria capsules), Limeolin (domperidone tablets)
Gynecological / assisted reproductive products include leuprorelin acetate microspheres for injection, Lishenbao (urinary follicle stimulating hormone for injection), Lebao (urinary gonadotropin for injection) and chorionic gonadotropin for injection.
The core products in the field of anti-infection are: antiviral particles, Kang Li Neng (cefodizine for injection), Lifukang (voriconazole for injection), Lizuwei (valaciclovir hydrochloride tablets)
The core products in the mental / neurological field are: Contin (Piropion Hydrochloride tablets), Repiride (Fluvoxamine Maleate tablets), Likang (Mouse nerve growth Factor for injection, National Class 1 New Drug)
Cardiovascular and cerebrovascular products include: valsartan capsule, amlodipine benzenesulfonate tablet, Xinnolilong (two-dimensional Sanqi cinnarizine capsule), pravastatin capsule, isosorbide mononitrate tablet, Xueshuantong injection.
The leading product of tumor medicine is Shenqi Fuzheng injection.
In the field of API, 15 products have the first market share in the world.
Research and development advantage
In recent years, the company has integrated R & D resources and increased R & D investment to form a R & D platform with Lizhu Research Institute, Lizhu Microspheres, Lizhu Monoclonal Antibody, Lizhu Raw Drug R & D Center and Lizhu traditional Chinese Medicine Department R & D Center as the core. It has three national R & D platforms: national traditional Chinese Medicine Modernization Engineering Technology Research Center, National recognized Enterprise Technology Center, and long-acting Microsphere Technology National Local Joint Engineering Research Center. There are four provincial R & D platforms in Guangdong Province: Guangdong High-tech Enterprises, Guangdong key Engineering Technology Research and Development Center, Guangdong Digital traditional Chinese Medicine Engineering Technology Research and Development Center, Guangdong cephalosporin Drug Engineering and Technology Research Center.
Lizhu Research Institute achieved secondary unit management in 2015 and has now become a comprehensive R & D institution with high-level and multi-field R & D capabilities. the research building is the R & D base of the research institute: the experimental area is 7770 square meters, the pilot workshop is more than 1000 square meters, and the office area is 1350 square meters. There are more than 500 sets of equipment for all kinds of analysis and testing, preparation research and pilot scale-up research, with a total value of more than 40 million yuan. The related instruments are: 905 automatic potentiometric titrator / polarimeter / aseptic isolator / ozone disinfector / biosafety cabinet / bacteria collector HTY-602A/ vertical pressure steam sterilizer and other imported advanced equipment.
Lizhu Microsphere Company, founded on July 3, 2017, is one of the earliest enterprises to develop microsphere products in China. In January 2013, Lizhu Group formally introduced the microsphere project platform, established the microsphere room of the Institute of Chemical Medicine, and won the title of "National Local Joint Engineering Research Center for long-lasting Microsphere Technology" in March 2015. there are 6 projects under research.
It won the sixth batch of innovative and entrepreneurial teams introduced by Guangdong Province's Pearl River Talent Plan in 2016, a special project supported by the industrialization of major scientific and technological achievements in Guangdong Province in 2016-2017, and a national major new drug creation project in 2017. The company has listed leuprorelin acetate microspheres for injection, mainly for the treatment of endometriosis and uterine leiomyoma, and is one of the earliest microrelease spheres in China.
Lizhu Monoclonal Antibody Company was jointly funded by Lizhu Group and Health Yuan Pharmaceutical Group in 2010. The main business is the technical research and development of biomedical products and antibody drugs, and the transfer of technological achievements, mainly biological innovative drugs, supplemented by biological generic drugs. McAb company has a world-class leadership team, with first-class innovation and industrialization ability.
The company plans to have the first product declared production (LZM003) in 2020, and after that, at least 1 new product is declared for production each year, accelerating the research and development of innovative drugs, at least 3 new projects will be introduced into clinical practice each year, optimize the clinical application capacity in Europe and the United States, improve the CAR-T R & D line, layout global innovation projects, expand independent production capacity, gradually achieve good business performance, and create considerable profits for shareholders and investors.
API R & D Center: Lizhu API R & D department integrates automation, machine learning and genomics. Use the genome as a search engine to tap the potential of microorganisms with high efficiency. Synthetic biology combined with microbial breeding as a tool to develop new API products and increase the yield of target strains. The R & D team has established five topics, covering bioinformatics, microbial strain improvement, fermentation optimization, peptide synthesis and API quality research. So far, through the use of the above genomic data and biological tools, more economical and reliable working strains have been successfully developed (such as acarbose, lovastatin, olivastatin, etc.).
There are four preparation manufacturing enterprises under Lizhu: Lizhu Group Lizhu Pharmaceutical Factory-located in Guangdong Lizhu Industrial Park, which is the leading production base of chemical and biological drugs in China; Shanghai Lizhu Pharmaceutical Co., Ltd.-located in Shanghai Jinqiao Development Zone, is the production base of chemical and biochemical drugs; Lizhu Group limin Pharmaceutical Factory-located in Shaoguan, Guangdong Province, is the production base of traditional Chinese medicine. Sichuan Everbright Pharmaceutical Co., Ltd.-located in Chengdu, Sichuan, is the production base of traditional Chinese medicine.
Lizhu Group API Division was established on June 26, 2015, headquartered in the people's Road, Qingyuan City, Guangdong Province, Lizhu Group New Beijiang Pharmaceutical Co., Ltd., is a research and development, production and sales of APIs as one of the headquarters enterprises. It is composed of Lizhu Group New Beijiang Pharmaceutical Co., Ltd. (Guangdong Qingyuan), Lizhu Group Ningxia Pharmaceutical Co., Ltd. (Ningxia Pingluo), Fuzhou Fuxing Pharmaceutical Co., Ltd. (Fuzhou Jiangyin, Ningde Gutian), Lizhu synthetic Pharmaceutical Co., Ltd. (Guangdong Zhuhai Free Trade Zone, Henan Jiaozuo). At present, the output value exceeds 2 billion and employs nearly 3000 people. The enterprises under the API Division are mainly engaged in the R & D, production and sales of human / veterinary APIs, pharmaceutical intermediates, food additives and other products.
Lizhu Group headquarters (Lizhu Industrial Park) is located in the Biopharmaceutical Industrial Park, Jinwan District, Zhuhai City, Guangdong Province, covering an area of more than 420000 square meters and an investment of more than 2 billion yuan. The foundation work began in July 2008, the first phase of the project was officially put into production in December 2010, and all the relocation was completed on November 28, 2016.
Lizhu Industrial Park is designed by IPI company of Germany and built in accordance with American FDA and European Pharmacopoeia COS (European Pharmacopoeia adaptability Certification) standards; advanced energy-saving control technology is adopted to achieve zero emission; hardware facilities such as automatic entry and exit freeze-dried powder injection production line, automatic three-dimensional elevated warehouse and logistics system, solid preparation workshop adopting foreign advanced technological concepts are all at the domestic first-class level.
Founded in 1989, Lizhu Reagent Co., Ltd. is a high-tech enterprise specializing in in vitro diagnostic reagents, instrument research and development, production and marketing under Lizhu Group. It has a perfect production quality management system and has passed the national GMP certification, GSP certification and German T ü V ISO13485/ISO9001 certification. It brings together elites in many fields, including laboratory medicine, bioengineering and so on. It has established many technical platforms such as enzyme-linked immunosorbent assay, colloidal gold, chemiluminescence, clinical biochemistry, microbiology and molecular detection, and has a strong multi-platform research and development capability. At the same time, Lizhu Reagent has actively expanded international cooperation and has established long-term and friendly cooperation with international first-class biomedical companies such as Alere of the United States, Fujirebio of Japan, MP of Singapore and Simens of Germany. The product field covers hepatitis, AIDS, sexually transmitted diseases, eugenics, drug concentration monitoring, tumor marker monitoring and blood nucleic acid screening and other areas, creating Lizhu characteristic disease management and testing.
In recent years, Lizhu Reagent has increased its investment in new technology platforms such as molecular nucleic acid detection and automation, chemiluminescence and liquid chip multiple immunity, and is developing a number of new projects to further strengthen the product variety and strength of enterprises. Especially during the COVID-19 epidemic period, the (2019-nCoV) IgM/IgG antibody detection kit (colloidal gold method) diagnostic kit developed by Lizhu reagent has been successfully put on the market.
Lizhu marketing headquarters has established a prescription drug sales network that radiates the whole country; it has built a marketing network and commercial main channels covering the national market; it covers 31 provinces and covers more than 400 cities; and it has established a network of experts for academic exchanges in different fields of treatment. The sales center of Lizhu API Division has established domestic and international sales networks. among them, 14 products such as acarbose, tobramycin sulfate, seramectin, milbexime, moxietin, Carla series products, mevastatin, lovastatin and mycophenolic acid have the first market share in the world.
Mission, goal, vision
To always be committed to the cause of human health as the mission!
To provide domestic first-class, international leading specialty medicine as the goal!
To revitalize the national pharmaceutical industry as its own responsibility, and strive to become the world's leading pharmaceutical enterprises as the vision!